ASLAN Pharmaceuticals and Bristol-Myers Squibb Enter Innovative Partnership

Bristol-Myers SquibbASLAN Pharmaceuticals Pte Ltd, a pharmaceutical company headquartered in Singapore, and Bristol-Myers Squibb Company (NYSE: BMY) announced an innovative strategic partnership allowing for the rapid development of BMS-777607, Bristol-Myers Squibb's investigational small molecule inhibitor of the MET receptor tyrosine kinase for treatment of solid tumors. This creative approach will accelerate the delivery of clinical proof-of-concept by leveraging the complementary strengths of an Asia-based drug development company and a global biopharmaceutical company.

Under the terms of the agreement, ASLAN will receive exclusive rights to develop and commercialize BMS-777607 in China, Australia, Korea, Taiwan and other selected Asian countries while Bristol-Myers Squibb retains exclusive rights in the rest of the world. ASLAN will run and fund development of BMS-777607 under a pre-agreed development program that will initially target gastric cancer and lung cancer. Financial terms were not disclosed.

"This ground-breaking partnership demonstrates how a leading Asian drug development company can work together with a global biopharmaceutical company to accelerate drug development and conduct early clinical studies in Asia in areas of significant unmet need," said Dr. Carl Firth, CEO of ASLAN.

"As part of our biopharma strategy, Bristol-Myers Squibb seeks to seed companies in key markets with promising investigational medicines of continued interest to Bristol-Myers Squibb," said Francis Cuss, senior vice president, Research, Bristol-Myers Squibb. "Dubbed our Oyster strategy, under this type of agreement partners like ASLAN run and fund early development, working closely with Bristol-Myers Squibb, to produce high-quality data that may be used to further develop and commercialize the medicine worldwide. We are pleased to be working with ASLAN to quickly further our understanding of this oncology compound for use in treating solid tumors."

About ASLAN
ASLAN Pharmaceuticals is an Asia-enabled pharmaceutical company that develops novel medicines for global markets, headquartered in Singapore. ASLAN licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases, and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Most Popular Now

AstraZeneca COVID-19 vaccine Vaxzevria authorised …

AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisat...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY®, the companie...

Takeda announces approval of Moderna's COVID-19 va…

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under...

Sanofi and GSK initiate global Phase 3 clinical ef…

Today, Sanofi and GlaxoSmithKline plc (GSK) started enrolment in their Phase 3 clinical study to assess the safety, efficacy and immunogenicity of their adjuvanted recomb...

Sanofi and GSK COVID-19 vaccine candidate demonstr…

The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who h...

European Commission approves Venclyxto-based combi…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidi...

Novartis reaches milestone delivery of 1 billion c…

Novartis announced that it has delivered one billion courses of antimalarial treatment since 1999. More than 90% of this artemisinin-based combination therapy (ACT) was s...

COVID-19 mRNA vaccines are immunogenic in pregnant…

Pregnant women with symptomatic COVID-19 have a higher risk of intensive care unit admissions, mechanical ventilation and death compared to non-pregnant reproductive age ...

Why are some COVID-19 vaccines working better for …

MSU researcher is studying, raising awareness about the role of sex in the efficacy of vaccines that make use of nanomedicine. If there's one take-home message for the...

Rogue antibodies wreak havoc in severe COVID-19 ca…

The development of antibodies to the COVID-19 virus has been the great long-term hope of ending the pandemic. However, immune system turncoats are also major culprits in ...

New vaccine platform: 'Two-one replicon-and-VLP-mi…

To stop the current SARS-CoV-2 pandemic, vaccines of high quality, safety, and efficacy are required. Scientists of the Paul-Ehrlich-Institut and the Ludwig Maximilian Un...

COVID-19 monoclonal antibodies reduce risk of hosp…

Monoclonal antibodies, a COVID-19 treatment given early after coronavirus infection, cut the risk of hospitalization and death by 60% in those most likely to suffer compl...